GlassScriptPhysician profile
Jack F Scheuer
NPI 1871544403
$3,739.50
in general payments reported to CMS, 2019-2025
30 companies · $283 in 2025
The $283 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,279 · 2020: $965 · 2021: $1,213 · 2025: $283.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $283.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $282.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $509.75 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $422.93 | 2019-2025 | Airsupra |
| Pfizer INC. | $355.94 | 2019-2021 | |
| Glaxosmithkline, LLC. | $303.98 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $282.87 | 2019-2021 | |
| Novo Nordisk INC | $232.93 | 2019-2025 | Ozempic |
| Amgen INC. | $232.46 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $181.18 | 2019-2021 | |
| Amarin Pharma, INC. | $171.38 | 2019-2021 | |
| Abbvie INC. | $121.12 | 2021 | |
| Davol INC. | $117.71 | 2025 | Phasix Mesh |
| Merck Sharp & Dohme LLC | $115.51 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $102.02 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $89.76 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $85.19 | 2019-2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $71.28 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $62.63 | 2019-2021 | |
| Astellas Pharma US INC | $54.55 | 2019-2021 | |
| Grifols USA, LLC | $46.48 | 2019-2021 | |
| Medtronic USA, INC. | $24.78 | 2019 | |
| Jazz Pharmaceuticals INC. | $19.62 | 2021 | |
| Sunovion Pharmaceuticals INC. | $19.27 | 2019 | |
| Nestle Healthcare Nutrition INC. | $19.11 | 2021 | |
| Arbor Pharmaceuticals, INC. | $18.54 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.47 | 2019 | |
| Boston Scientific Corporation | $13.61 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $13.50 | 2021 | |
| Eisai INC. | $12.29 | 2020 | |
| Mylan Specialty L.P. | $12.00 | 2019 | |
| Seqirus USA INC | $11.64 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jack Scheuer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.